Imprida

RSS

amlodipine / valsartan

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Imprida has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 11/05/2017

Authorisation details

Product details
Name
Imprida
Agency product number
EMEA/H/C/000775
Active substance
  • amlodipine (as besylate)
  • valsartan
International non-proprietary name (INN) or common name
amlodipine / valsartan
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09DB01
Publication details
Marketing-authorisation holder
Novartis Europharm Ltd
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
17/01/2007
Contact address
Frimley Business Park
Camberley GU16 7SR
United Kingdom

Product information

03/04/2017 Imprida - EMEA/H/C/000775 - WS/0709

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating